The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization

Abstract

Topically administered bevacizumab at a concentration of 4 mg/ml significantly reduces corneal NV according to both clinical and histopathological evaluations; lower concentrations were less effective on both parameters. No corneal epitheliopathy was found using these concentrations.